Results 81 to 90 of about 412,643 (184)
Journal of Diabetes Investigation, 2020 A 38‐year‐old woman with type 1 diabetes, whose fasting plasma glucose levels were >500 mg/dL under 176 U/day of subcutaneous insulin injection, was admitted to Nippon Medical School Hospital, Tokyo, Japan.
Yuko Nakamura +7 more
doaj +1 more source
Insulin Treatment for Gestational Diabetes Mellitus
ObgyniaIntroduction: Gestational diabetes is one of the most common pathologies in pregnancy that can potentially cause other complications, both to the mother and the fetus.
I Gde Sastra Winata +4 more
doaj +1 more source
Basal insulin analogues in the treatment of diabetes mellitus: What progress have we made?
Indian Journal of Endocrinology and Metabolism, 2015 Over the past few decades, continuous progress has been made in the development of insulin therapy. Basal insulins were developed around 60 years ago. However, existing basal insulins were found to have limitations. An ideal basal insulin should have the
Sanjay Kalra
doaj +1 more source
, 2008 Some studies have shown that fetal outcome observed in patients using insulin lispro is much the same as in pregnant women using regular insulin. This study aims to analyze the Italian data emerging from a multinational, multicenter, retrospective study ...
M. G. Dalfra +22 more
core +2 more sources
Diabetology & Metabolic Syndrome, 2011 In order to provide comprehensive information on the differences in bioactivity between human insulin and insulin analogues, published in vitro comparisons of human insulin and the rapid acting analogues insulin lispro (Humalog®), insulin aspart ...
Werner Haim, Chantelau Ernst A
doaj +1 more source
Vascular effects of rapid-acting insulin analogs in the diabetic patient: a review
Vascular Health and Risk Management, 2009 Steve Fordan, Philip RaskinDepartment of Medicine, Division, of Endocrinology, University of Texas, Southwestern Medical Center, Dallas, TX, USAAbstract: The insulin analogs lispro, aspart, and glulisine are the only commercially available rapid-acting ...
Steve Fordan, Philip Raskin
doaj
Clinical Diabetes and Endocrinology, 2017 Background Rapid-acting insulin analogs (RAIs) have not been examined for long-term safety in randomized clinical trials. We performed a nationwide longitudinal cohort study among individuals with type 2 diabetes (T2DM) to address cardiovascular safety ...
Ann-Marie Svensson +3 more
doaj +1 more source
Diabetes, Metabolic Syndrome and Obesity, 2016 Linong Ji,1 Kyung Wan Min,2 Juliana Oliveira,3 Thomas Lew,4 Ran Duan3 1Department of Endocrinology, Peking University People's Hospital, Beijing, People's Republic of China; 2Department of Endocrinology, Eulji Hospital, Seoul, Republic of Korea ...
Ji L, Min KW, Oliveira J, Lew T, Duan R
doaj
Immediate and Late Onset Forms of Insulin Hypersensitivity Presenting with Glucose Dysregulation
Endocrinology Research and Practice, 2018 We report the case of a 35-year-old woman allergic to detemir, neutral protamine Hagedorn, and glargine. Initially, local reactions to the insulin preparations occurred, which continued even after the types of insulin and the application areas were ...
Ceyda TUNAKAN DALGIÇ +4 more
doaj
Vascular Health and Risk Management, 2007 Heather Ulrich1,4, Benjamin Snyder1,Satish K Garg1,2,31Barbara Davis Center for Childhood Diabetes; 2Department of Medicine; 3Pediatrics; 4Department of Clinical Pharmacy, School of Pharmacy, University of Colorado at Denver and Health Sciences Center ...
Heather Ulrich +2 more
doaj